Listing Conditions –

Euronext Dublin Primary Checklist

# **(Commercial Companies including Mineral and Scientific Research Companies)**

|  |  |
| --- | --- |
| Name of Company |       |
| Nature of Transaction |       |
| Name of Sponsor |       |
| Date submitted |       |
|  |

| Rule | Requirement | Page | Proof number | Comment (where applicable) |
| --- | --- | --- | --- | --- |
| **Rule 6.2 Book I**  |  |  |  |  |
| 6201(i)  | Legal form of issuer must be in accordance with laws and regulations |       |       |       |
| 6201(ii)  | Issuer must comply with any relevant competent authority |       |       |       |
| 6201(iii)  | Adequate procedures for clearing and settlement |       |       |       |
| 6201 (iv)  | ISIN and LEI |       |       |       |
| 6202  | Securities of same class have identical rights |       |       |       |
| 6203 | Securities validly issued |       |       |       |
| 6204 | Form of securities comply with national regulations |       |       |       |
| 6205  | Securities traded in a fair, orderly and efficient manner and are freely negotiable |       |       |       |
| 6206(i)(ii)  | Underlying securities are traded or will be traded on a regulated market or equivalent |       |       |       |
| 6207 | Whole class to be listed |       |       |       |
| **Rule 2.1 Book II** |  |  |  |  |
| 2.1.3  | Operating in conformity with constitutional documents |       |       |       |
| 2.1.4(1)  | Admitted on RIE |       |       |       |
| 2.1.4(2)  | Compliance with stock exchange where securities admitted to trading  |       |       |       |
| 2.1.5(2) | Fully paid |       |       |       |
| 2.1.8(1) | Minimum market capitalisation |       |       |       |
| 2.1.10(2) | Prospectus approved by Member State and published |       |       |       |
| 2.1.11(1) | Convertible into listed securities |       |       |       |
| 2.1.11(2)(3)  | Convertible into recognised market securities |       |       |       |
| 2.1.13 | Warrants or options to subscribe |       |       |       |
| **Rule 6.3 Book I**  |  |  |  |  |
| 6302/1(ii)  | Accounts for three years |       |       |       |
| 6302/1(ii)  | Accounts consolidated |       |       |       |
| 6302/1(ii) | IFRS accounting standards or equivalent |       |       |       |
| **Rule 2.2 Book II** |  |  |  |  |
| 2.2.4(1)(a)  | 6/9 month rule |       |       |       |
| 2.2.4(1)(b)  | Audited without modification (unless LR 2.2.5 or LR 10.6.18 applies) |       |       |       |
| 2.2.4(2)(a)  | Independent auditors providing opinion |       |       |       |
| 2.2.4(2)(b)  | Auditors confirmation  |       |       |       |
| 2.2.6 (1) | 75% of business |       |       |       |
| 2.2.6 (2)  | Put investors in a position to make informed assessment  |       |       |       |
| 2.2.8 (1) | Historical financial information related to acquired entities for 3 years |       |       |       |
| 2.2.8(2) | Consistent with accounting policies adopted |       |       |       |
| 2.2.8(3) | Not subject to a Modified Report (unless LR 2.2.5 applies) |       |       |       |
| 2.2.8 (4)  | represents 75% of enlarged business |       |       |       |
| 2.2.11 | Independent business as main activity  |       |       |       |
| 2.2.13(1) | Written agreement with controlling shareholder |       |       |       |
| 2.2.14(1) | Agreement with appropriate number of controlling shareholders in light of understanding |       |       |       |
| 2.2.14(2)(a) | Agreement includes procurement provision |       |       |       |
| 2.2.14(2)(b) | Agreement includes names of non-signing controlling shareholders |       |       |       |
| 2.2.15(1) | Agreement includes undertaking regarding transactions |       |       |       |
| 2.2.15(2) | Agreement includes undertaking regarding compliance with obligations under LR’s |       |       |       |
| 2.2.15(3) | Agreement includes undertaking regarding resolutions |       |       |       |
| 2.2.24 | Working capital |       |       |       |
| 2.2.26(1)  | Banking, Insurance or financial services company |       |       |       |
| 2.2.26(2) | Solvency and capital adequacy is regulated |       |       |       |
| 2.2.26(3)  | Meeting capital adequacy requirements and is expected to do so for 12 months |       |       |       |
| 2.2.27 | Shares in public hands |       |       |       |
| 2.2.32 | Warrants limited to 20% |       |       |       |
| 2.2.33(1)  | Pre-emption rights – constitution provides at least equivalent rights to LR 6.1.30 |       |       |       |
| 2.2.33(2)  | Conferring such rights not incompatible with law of country of incorporation  |       |       |       |
| 2.2.34 | Discretion of board not limited or transferred and board capable to act on key strategic matters  |       |       |       |
| 2.2.36 | Constitution will allow it to comply with LR 6.1.22 |       |       |       |
|  | **Mineral Company** |  |  |  |
| 2.2.16  | Published or filed historical financial information since inception  |       |       |       |
| 2.2.18  | Reasonable spread of direct interests and rights to participate in extraction |       |       |       |
|  | **Scientific Research Based Company** |  |  |  |
| 2.2.19  | Published or filed historical financial information since inception |       |       |       |
| 2.2.20(1)  | Demonstrate ability to attract funds from sophisticated investors |       |       |       |
| 2.2.20(2)  | Raising at least €12.5m |       |       |       |
| 2.2.20(3)  | Market cap before fundraising of €25m |       |       |       |
| 2.2.20(4)  | Use finance to bring identified product to revenue generating stage |       |       |       |
| 2.2.20(5)  | Demonstrate that it has 3 year record of operations in laboratory research and development including:1. details of patents granted or details of progress of patent applications; and
2. successful completion of, or the successful progression of, significant testing of the effectiveness of its products
 |       |       |       |

|  |
| --- |
| Non-applicability Confirmation |
| We inform you that items marked ‘N/A’ in the Page column of the above checklist are considered not applicable and no equivalent information is available. |
|  |
| Signed by |
|  |  |
| on behalf of |       |

Your attention is drawn to the Privacy Statement of the Irish Stock Exchange trading as Euronext Dublin, accessible at: <http://www.ise.ie/Privacy-Statement/>. This outlines how and why your personal data may be processed by us when you, or a company with which you are connected, engage with us or avail of our services. If you are acting on behalf of a company engaging with or availing of the services of Euronext Dublin, you must ensure that our Privacy Statement has been brought to the attention of all persons whose personal data we may process in the course of our relationship with your company (e.g. agents, officers, employees and other personnel).